KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accounts Payables (2016 - 2025)

TherapeuticsMD's Accounts Payables history spans 16 years, with the latest figure at $377000.0 for Q4 2025.

  • For Q4 2025, Accounts Payables rose 46.12% year-over-year to $377000.0; the TTM value through Dec 2025 reached $377000.0, up 46.12%, while the annual FY2025 figure was $377000.0, 46.12% up from the prior year.
  • Accounts Payables reached $377000.0 in Q4 2025 per TXMD's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $20.8 million in Q1 2022 to a low of $176000.0 in Q1 2025.
  • Average Accounts Payables over 5 years is $5.9 million, with a median of $2.7 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: crashed 94.8% in 2023, then soared 304.89% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $3.4 million in 2021, then crashed by 35.9% to $2.2 million in 2022, then skyrocketed by 44.91% to $3.1 million in 2023, then tumbled by 91.77% to $258000.0 in 2024, then skyrocketed by 46.12% to $377000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Accounts Payables are $377000.0 (Q4 2025), $2.0 million (Q3 2025), and $1.6 million (Q2 2025).